Becton Dickinson (BDX) is Downgraded by Morgan Stanley to Equal-Weight , according to the research report released to the investors. Earlier the firm had a rating of Overweight on the company shares. The shares recommendation by the Brokerage Firm was released on Jan-4-2016.
Becton, Dickinson and Company is up 17.07% in the last 3-month period. Year-to-Date the stock performance stands at 12.63%.
Becton, Dickinson and Company (NYSE:BDX) has lost 1.17% during the past week and dropped 0.47% in the last 4 weeks. The shares have underperformed the S&P 500 by 0.34% during the past week but Becton, Dickinson and Company (NYSE:BDX) has outperformed the index in 4 weeks by 1.86%.
Shares of Becton, Dickinson and Company (NYSE:BDX) ended Thursday session in red amid volatile trading. The shares closed down 1.34 points or 0.86% at $154.09 with 1,087,662 shares getting traded. Post opening the session at $154.73, the shares hit an intraday low of $154.08 and an intraday high of $155.45 and the price vacillated in this range throughout the day. The company has a market cap of $32,472 million and the number of outstanding shares have been calculated to be 210,736,540 shares. The 52-week high of Becton, Dickinson and Company (NYSE:BDX) is $157.5 and the 52-week low is $128.87.
Currently the company Insiders own 1.6% of Becton, Dickinson and Company shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -22.01% . Institutional Investors own 84.4% of Becton, Dickinson and Company shares. During last six month period, the net percent change held by insiders has seen a change of -22.01%. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, Sichak Stephen, officer (Executive Vice President) of Becton Dickinson & Co, unloaded 8,670 shares at an average price of $152.21 on December 14, 2015. The total amount of the transaction was worth $1,319,661, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Becton Dickinson and Co is a global medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Companys operations consist of three business segments: BD Medical, BD Diagnostics and BD Biosciences. BD Medical produces a range of medical devices, which are used in a range of healthcare settings. BD Biosciences produces research and clinical tools that facilitate the study of cells, and the components of cells. BD Diagnostics provides products for the safe collection and transport of diagnostics specimens. On March 11, 2013, the Company acquired a 100% interest in Cato Software Solutions (Cato).